Zydus Cadila gets tentative USFDA nod for cancer cure

The group now has more than 100 approvals and has filed over 280 ANDAs

Drug firm Zydus Cadila has received tentative nod from the US health regulator to market Clofarabine injection, used for treatment of cancer of the white blood cells, in the American market.

"Zydus Cadila has received the tentative approval from the United States Food and Drug Administration (USFDA) to market Clofarabine injection 20mg/20ml vials," Cadila Healthcare said in a BSE filing.

Read more from our special coverage on "ZYDUS CADILA"

• Zydus Cadila gets USFDA nod for anti-diabetics tablets
• Zydus to commence supplies to US from facility at Ahmedabad SEZ

The group now has more than 100 approvals and has filed over 280 abbreviated new drug applications (ANDAs) since the commencement of the filing process in financial year 2003-04, it added.

Clofarabine is used to treat acute lymphoblastic leukemia (a type of cancer of the white blood cells) of 1-21 years old pediatric patients.

Cadila Healthcare stock closed 2.56 per cent up at Rs 344.10 on BSE.